TG Therapeutics Says Data From ULTIMATE I & II Phase 3 Trials Of BRIUMVI In Multiple Sclerosis To Be Presented At 2023 Consortium Of Multiple Sclerosis Centers Meeting
Portfolio Pulse from Benzinga Newsdesk
TG Therapeutics announced that data from the ULTIMATE I & II Phase 3 trials of BRIUMVI in multiple sclerosis will be presented at the 2023 Consortium of Multiple Sclerosis Centers Meeting.
June 02, 2023 | 1:17 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
TG Therapeutics' stock may be positively impacted by the presentation of BRIUMVI Phase 3 trial data in multiple sclerosis at the 2023 CMSC Meeting.
The presentation of positive data from the ULTIMATE I & II Phase 3 trials of BRIUMVI in multiple sclerosis at the 2023 CMSC Meeting could increase investor confidence in TG Therapeutics and its product pipeline, potentially leading to a short-term increase in the stock price.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100